ASH 2024: Updates in the Treatment of CLL - Episode 2

ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL

Panelists discuss how long-term SEQUOIA trial data presented at ASH 2024 inform the selection between covalent BTK inhibitors zanubrutinib and acalabrutinib in treatment-naive CLL, including considerations for combining these agents with obinutuzumab.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi
    Now Viewing
    EP. 2: ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL
    EP. 3: Real-World Observations: Firstline cBTKi Switches and Cardiac AEs in TN CLL
    EP. 4: Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials
    EP. 5: Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in TN CLL
    EP. 6: ASH 2024 Updates: Evaluating Potential Frontline Triplet Regimen: Pirtobrutinib Plus Venetoclax Plus Obinutuzumab in TN CLL
    EP. 7: Expert Perspectives: Navigating the Emerging Treatment Landscape of Combination Therapies in TN CLL—Applying Evidence to Clinical Practice
    EP. 8: Expert Insights: Treatment Selection in Second-Line R/R CLL and Limitations of Applying MAIC Data in the Real-World Practice Setting
    EP. 9: ASH 2024 Highlights: Phase 2 Study of Zanubrutinib Plus Venetoclax in R/R CLL
    EP. 10: Treatment Sequencing in R/R CLL: Optimizing Strategies and Clinical Insights From ASH 2024 Real-World Data
    EP. 11: Pirtobrutinib in R/R CLL: Can It Be Used in the Second-Line Setting?
    EP. 12: Sequencing Treatment in R/R CLL: CAR T-Cell Therapy vs Pirtobrutinib in Double-Exposed Patients
    EP. 13: Real-World Observations With Pirtobrutinib and New Data From the BRUIN CLL-321 Trial at ASH 2024
    EP. 14: Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024
    EP. 15: Reflecting on 2024 in CLL: Key Advances and Looking Ahead to 2025

    Video content above is prompted by the following:

    • SEQUOIA researchers presented their 5-year follow-up data at this year’s ASH 2024 — could you share key updates from their abstract as well as your impressions? Do these data influence your decision when selecting among the covalent BTKi in treatment-naive CLL? 
    • How do you decide between acala vs zanu? In which patients would you consider adding obinutuzumab?
    x